Literature DB >> 19137112

Increased potency and longevity of gene silencing using validated Dicer substrates.

E Hefner1, K Clark, C Whitman, M A Behlke, S D Rose, A S Peek, T Rubio.   

Abstract

Chemically synthesized small interfering RNAs (siRNAs) are tools used for silencing the expression of a single gene. They are mainly employed in basic research applications, but may also have great potential in therapeutic applications. Longer double-stranded RNAs, such as Dicer-substrate 27mers, trigger gene silencing through the intrinsic RNAi pathway. The design of these Dicer-substrate 27mers has been optimized so they can be oriented by Dicer to consistently select the antisense (guide) strand after cleavage to shorter siRNAs, leading to predictable mRNA cleavage. In this paper we describe evidence that these Dicer-substrate 27mers produce more potent and sustained gene silencing for four genes when compared with synthetic 21mers that have the same guide-strand sequence. Furthermore, improved silencing by these 27mers is often more pronounced at lower concentrations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19137112      PMCID: PMC2567136     

Source DB:  PubMed          Journal:  J Biomol Tech        ISSN: 1524-0215


  27 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

Review 2.  The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis.

Authors:  Michelle A Carmell; Zhenyu Xuan; Michael Q Zhang; Gregory J Hannon
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

Review 3.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

4.  siDirect: highly effective, target-specific siRNA design software for mammalian RNA interference.

Authors:  Yuki Naito; Tomoyuki Yamada; Kumiko Ui-Tei; Shinichi Morishita; Kaoru Saigo
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

Review 5.  Post-transcriptional gene silencing by siRNAs and miRNAs.

Authors:  Witold Filipowicz; Lukasz Jaskiewicz; Fabrice A Kolb; Ramesh S Pillai
Journal:  Curr Opin Struct Biol       Date:  2005-06       Impact factor: 6.809

Review 6.  RNAi: the nuts and bolts of the RISC machine.

Authors:  Witold Filipowicz
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

7.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

8.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways.

Authors:  Dianne S Schwarz; György Hutvágner; Benjamin Haley; Phillip D Zamore
Journal:  Mol Cell       Date:  2002-09       Impact factor: 17.970

Review 9.  Therapeutic potential of RNA interference against cancer.

Authors:  Fumitaka Takeshita; Takahiro Ochiya
Journal:  Cancer Sci       Date:  2006-08       Impact factor: 6.716

10.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.

Authors:  Gunter Meister; Markus Landthaler; Agnieszka Patkaniowska; Yair Dorsett; Grace Teng; Thomas Tuschl
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

View more
  11 in total

1.  Viral RNAi suppressor reversibly binds siRNA to outcompete Dicer and RISC via multiple turnover.

Authors:  Renata A Rawlings; Vishalakshi Krishnan; Nils G Walter
Journal:  J Mol Biol       Date:  2011-02-24       Impact factor: 5.469

Review 2.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

3.  Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro.

Authors:  Shyam Ramachandran; Sateesh Krishnamurthy; Ashley M Jacobi; Christine Wohlford-Lenane; Mark A Behlke; Beverly L Davidson; Paul B McCray
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-26       Impact factor: 5.464

4.  Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury.

Authors:  Simone Alidori; Nima Akhavein; Daniel L J Thorek; Katja Behling; Yevgeniy Romin; Dawn Queen; Bradley J Beattie; Katia Manova-Todorova; Magnus Bergkvist; David A Scheinberg; Michael R McDevitt
Journal:  Sci Transl Med       Date:  2016-03-23       Impact factor: 17.956

5.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

6.  Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1.

Authors:  Cameron R Stewart; Adam J Karpala; Sue Lowther; John W Lowenthal; Andrew G Bean
Journal:  PLoS One       Date:  2011-07-01       Impact factor: 3.240

7.  Functional inhibition of chemokine receptor CCR2 by dicer-substrate-siRNA prevents pain development.

Authors:  Valérie Bégin-Lavallée; Élora Midavaine; Marc-André Dansereau; Pascal Tétreault; Jean-Michel Longpré; Ashley M Jacobi; Scott D Rose; Mark A Behlke; Nicolas Beaudet; Philippe Sarret
Journal:  Mol Pain       Date:  2016-06-15       Impact factor: 3.395

8.  Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.

Authors:  Kim A Lennox; Mark A Behlke
Journal:  Nucleic Acids Res       Date:  2015-11-17       Impact factor: 16.971

Review 9.  siRNA Versus miRNA as Therapeutics for Gene Silencing.

Authors:  Jenny K W Lam; Michael Y T Chow; Yu Zhang; Susan W S Leung
Journal:  Mol Ther Nucleic Acids       Date:  2015-09-15       Impact factor: 10.183

Review 10.  Editorial focus: understanding off-target effects as the key to successful RNAi therapy.

Authors:  Rafal Bartoszewski; Aleksander F Sikorski
Journal:  Cell Mol Biol Lett       Date:  2019-12-09       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.